Indeed, during the total 16 years of observation, many radical changes in the clinical management of RCC occurred, including the introduction of next-generation VEGFR-TKIs and ICIs into the therapeutic armamentarium and the advent of VEGFR-TKI plus ICI combinations. The gene discussed is KDR; the disease is renal cell carcinoma.